Enalapril

Vasotec/Epaned treat hypertension, alone or with other antihypertensives. Epaned hypertension indication includes children older than 1 month with the label’s neonatal/preterm/renal restrictions. Oral therapy also treats symptomatic heart failure, improving survival and reducing hospitalization in selected trials, and reduces progression to overt failure/hospitalization in clinically stable asymptomatic LV dysfunction with EF≤35%. Trial-era descriptions of diuretics/digitalis are not a complete current guideline combination regimen.

The active drug enalaprilat injection treats hypertension when oral therapy is not practical. It is not the enalapril prodrug, an oral solution, or an automatically interchangeable HF IV regimen. Selected IV pediatric efficacy/safety is unestablished.

The 2022 AHA/ACC/HFSA guidance supports ACE inhibition for prior/current symptomatic chronic HFrEF when ARNI therapy is not feasible. It recommends selected MRAs in symptomatic HFrEF with appropriate kidney function/potassium and close monitoring. The older Vasotec statement generally avoiding potassium-sparing agents in HF is therefore not a blanket prohibition of specialist-planned contemporary combinations. This profile does not supply the complete HF regimen.

Epaned is ready-to-use 1 mg/mL ENALAPRIL MALEATE; its package states 1 mg maleate equivalent to 0.764 mg enalapril per mL. Use prescribed labeled mg and calibrated oral syringe; do not recalculate the routine dose to free-base mg without pharmacy direction. Vasotec’s label provides a separate pharmacist-prepared 1 mg/mL suspension using ten 20 mg tablets,50 mL citrate/citric-acid oral solution and 150 mL Ora-Sweet SF, with timed mixing/standing and refrigerated 30-day storage; shake that suspension before use. This is not Epaned’s 60-day room-temperature rule or a home compounding recommendation.

Titration and first-dose observation are indication-specific. Hold/reduce concomitant diuretic only when clinically appropriate, with BP/volume/renal assessment. Selected labels do not supply a universal hepatic percentage adjustment, missed-dose catch-up algorithm or switch equivalence; obtain exact-product pharmacy instructions.

Selected oral products: product/ACE-inhibitor-related hypersensitivity or prior ACE-related angioedema, hereditary/idiopathic angioedema, aliskiren coadministration in diabetes, and neprilysin-inhibitor combination. Observe≥36-hour interval when switching to/from sacubitril/valsartan. Selected older IV label explicitly lists product hypersensitivity and ACE-related/hereditary/idiopathic angioedema; do not interpret its shorter formal list as permission to combine ACE inhibition with current prohibited oral combinations.

Vasotec and Epaned box fetal toxicity: stop as soon as pregnancy detected. Selected related enalaprilat injection carries a boxed use-in-pregnancy warning describing fetal injury/death in second/third trimester and prompt discontinuation. These are distinct from a claim that pregnancy is listed in every formal contraindications section.

Cough, fatigue, rash, dizziness and orthostatic effects are reported; hypotension is more common in HF. Other reports include renal dysfunction, hyperkalemia, severe skin reactions, neutropenia and angioedema. Trial/postmarketing rates differ and may not prove causation. Overdose is expected principally to cause hypotension: seek Poison Help/emergency assessment and supervised supportive treatment. Enalaprilat can be removed by hemodialysis; this is not a home rescue plan or guarantee of efficacy in every overdose.

Diuretics and other pressure-lowering agents may increase first-dose hypotension; adjust only with supervision. Injectable gold can cause flushing, nausea/vomiting and hypotension. IV enalaprilat has related additive hypotension, potassium and lithium risks. Lack of a major PK interaction does not exclude clinical renal/pressure effects.

Discontinue oral enalapril/related IV enalaprilat as soon as pregnancy detected; seek alternative management. Fetal surveillance and exposed-neonate BP/renal/potassium assessment require specialist care. Epaned advises no breastfeeding because milk contains enalapril/enalaprilat and serious infant hypotension/hyperkalemia/renal risks are possible. Vasotec/IV labels instead describe choosing between nursing and therapy according to maternal need; reconcile exact formulation with clinician, not an unqualified ingredient-wide safety claim.

Oral hypertension: Vasotec evidence starts at 1 month, while Epaned requires older than 1 month; exactly1 month needs product review, respecting Epaned’s preterm 44-week and pediatric GFR exclusions; pivotal efficacy trial enrolled 6–16 years and younger support is more limited. No pediatric HF/LV dysfunction or IV dose established. Older patients need cautious selection and renal monitoring because clearance is renal; no fixed age-only percentage formula is supplied.

Adult CrCl dose table uses mL/min; pediatric GFR restriction uses mL/min/1.73 m². Reduced renal clearance prolongs enalaprilat exposure and dialysis affects timing. No routine hepatic adjustment table is provided; liver injury requires stop/review. ACE-inhibitor monotherapy lowers BP less on average in Black patients, while angioedema risk is higher; these population findings do not create a race-based dosing formula.

Enalaprilat inhibits ACE, reducing angiotensin II formation and aldosterone release and increasing renin activity through feedback. ACE also degrades bradykinin; this helps explain relevant class effects, while the precise contribution to BP benefit is incompletely defined. Reduced aldosterone contributes to potassium rise.

Oral enalapril is hydrolyzed to enalaprilat, which peaks about 3–4 hours after oral dosing. Enalaprilat effective accumulation half-life is about 11 hours in adults, prolonged with substantial renal impairment. Elimination is largely renal; dialysis removes enalaprilat. Ready-to-use Epaned has verified product-specific bioequivalence studies, not a guarantee for arbitrary compounded liquids. IV administration delivers active drug directly; prolonged terminal binding/renal effects do not justify mg-for-mg oral conversion.

Assess baseline BP, volume status, kidney function and potassium; recheck during initiation/titration, renal/diuretic changes and interacting-drug use. High-risk patients need close initial observation and follow-up; no universal creatinine percentage stop-rule or routine lab interval is supplied. Consider WBC monitoring with renal plus collagen vascular disease. Promptly evaluate jaundice, syncope, oliguria or substantial potassium rise.

Report suspected pregnancy immediately; stop for airway/facial swelling and obtain urgent help. Consult clinician about dehydration, vomiting/diarrhea, potassium salt substitutes and NSAIDs. Verify liquid concentration, maleate units and exact storage dates with pharmacist; Epaned is ready-to-use and is not the Vasotec compounded suspension. Tell dialysis/desensitization/anesthesia teams about ACE-inhibitor therapy. Do not self-switch to sacubitril/valsartan.

5 mg tablet

White rounded-triangle tablet, VASO 5 on one side, scored on other.

Package

Bausch · NDC 0187-0141-30, bottle 30 with desiccant.

Status

Prescription oral ACE inhibitor; no automatic substitution for enalaprilat injection.

Vasotec

2.5,5,10,20 mg enalapril maleate tablets, different shapes/colors and VASO strength markings.

Epaned

1 mg/mL enalapril maleate, clear/colorless mixed-berry ready-to-use solution,150 mL; NDC 52652-4001-1.

Pharmacist-prepared suspension

Separate Vasotec label 1 mg/mL formulation using exact vehicles/mixing instructions; not an arbitrary home liquid.

Related IV active drug

Enalaprilat 1.25 mg/mL; selected Dr. Reddy’s vials 1.25 mg/mL and 2.5 mg/2 mL, IV only.

Vasotec 25°C, excursions 15–30°C, tight container and protect moisture. Epaned manufacturer refrigeration 2–8°C, tightly closed; patients may refrigerate or keep 20–25°C, but discard after 60 days if room-temperature storage. Avoid freezing/excess heat. Exact pharmacist-prepared Vasotec suspension refrigerates 2–8°C up to 30 days and must be shaken before use. Enalaprilat 20–25°C; selected compatible IV dilutions retain activity 24 hours at room temperature, subject to sterile local policy. Never apply one liquid’s storage rule to another.